Outsourcing supply chain and buffer preparation activities

As the biopharmaceutical market evolves and continues a steep upward trajectory of growth, biopharmaceutical drug innovators increasingly rely on contract development and manufacturing organizations (CDMOs) to help them achieve their mission.

The CDMO market segment is expected to achieve a CAGR of 11.3% by 2024.1 There are several factors contributing to this growth:

• An increase of emerging innovator companies without the resources to scale-up quickly to commercial manufacturing.
• A shift in therapeutic trends toward gene and cell therapies, biosimilars, and the emergence of monoclonal antibody-based (mAb-based) modalities under development, including antibody drug conjugates (ADCs), fusion proteins, and bispecific antibodies (bsAbs)
• A continued increase of traditional modalities such as mAbs, vaccines, and classical recombinant proteins

Given this growth and the reach it has across the Americas, Europe, and Asia-Pacific, it is critical that CDMOs are strategic in their growth models, finding ways to focus on unmet needs, deliver innovative solutions to capture investment opportunities, optimize costs, and reduce inefficiencies.